Chemoinformaics analysis of TETRADECAN-4-YL 2,2,2-TRIFLUOROACETATE
| Molecular Weight | 310.4 | nRot | 12 |
| Heavy Atom Molecular Weight | 281.168 | nRig | 0 |
| Exact Molecular Weight | 310.212 | nRing | 0 |
| Solubility: LogS | -4.401 | nHRing | 0 |
| Solubility: LogP | 4.209 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 50 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 21 | No. of Aromatic Carbocycles | 0 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 29 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 16 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 49.332 |
| nHD | 0 | BPOL | 35.036 |
| QED | 0.529 |
| Synth | 2.408 |
| Natural Product Likeliness | 0.653 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.003 |
| HIA | 0.004 |
| CACO-2 | -4.257 |
| MDCK | 0.0000212 |
| BBB | 0.947 |
| PPB | 0.891114 |
| VDSS | 1.904 |
| FU | 0.0787748 |
| CYP1A2-inh | 0.931 |
| CYP1A2-sub | 0.739 |
| CYP2c19-inh | 0.335 |
| CYP2c19-sub | 0.883 |
| CYP2c9-inh | 0.655 |
| CYP2c9-sub | 0.741 |
| CYP2d6-inh | 0.017 |
| CYP2d6-sub | 0.084 |
| CYP3a4-inh | 0.044 |
| CYP3a4-sub | 0.232 |
| CL | 11.475 |
| T12 | 0.391 |
| hERG | 0.013 |
| Ames | 0.005 |
| ROA | 0.042 |
| SkinSen | 0.257 |
| Carcinogencity | 0.069 |
| EI | 0.99 |
| Respiratory | 0.311 |
| NR-Aromatase | 0.002 |
| Antiviral | Yes |
| Prediction | 0.721084 |